Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications
- PMID: 28866268
- PMCID: PMC5656087
- DOI: 10.1016/j.yrtph.2017.08.019
Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications
Abstract
Physiologically based kinetic (PBK) models are used widely throughout a number of working sectors, including academia and industry, to provide insight into the dosimetry related to observed adverse health effects in humans and other species. Use of these models has increased over the last several decades, especially in conjunction with emerging alternative methods to animal testing, such as in vitro studies and data-driven in silico quantitative-structure-activity-relationship (QSAR) predictions. Experimental information derived from these new approach methods can be used as input for model parameters and allows for increased confidence in models for chemicals that did not have in vivo data for model calibration. Despite significant advancements in good modelling practice (GMP) for model development and evaluation, there remains some reluctance among regulatory agencies to use such models during the risk assessment process. Here, the results of a survey disseminated to the modelling community are presented in order to inform the frequency of use and applications of PBK models in science and regulatory submission. Additionally, the survey was designed to identify a network of investigators involved in PBK modelling and knowledgeable of GMP so that they might be contacted in the future for peer review of PBK models, especially in regards to vetting the models to such a degree as to gain a greater acceptance for regulatory purposes.
Keywords: Alternatives methods; PBK models; Physiologically based kinetic models; Regulatory; Risk assessment; Toxicology.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.Arch Toxicol. 2022 Dec;96(12):3407-3419. doi: 10.1007/s00204-022-03356-5. Epub 2022 Sep 5. Arch Toxicol. 2022. PMID: 36063173 Free PMC article.
-
Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose-response curves for developmental toxicity of phenol in rat and human.Arch Toxicol. 2013 Sep;87(9):1709-23. doi: 10.1007/s00204-013-1107-4. Epub 2013 Aug 14. Arch Toxicol. 2013. PMID: 23943240
-
Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making.Comput Toxicol. 2019 Feb;9:61-72. doi: 10.1016/j.comtox.2018.11.002. Comput Toxicol. 2019. PMID: 31008414 Free PMC article. Review.
-
Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.Toxicol Sci. 2017 Jun 1;157(2):365-376. doi: 10.1093/toxsci/kfx054. Toxicol Sci. 2017. PMID: 28498972
-
Gaining acceptance in next generation PBK modelling approaches for regulatory assessments - An OECD international effort.Comput Toxicol. 2021 May;18:100163. doi: 10.1016/j.comtox.2021.100163. Comput Toxicol. 2021. PMID: 34027244 Free PMC article. Review.
Cited by
-
Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Mar 23;14:1165770. doi: 10.3389/fphar.2023.1165770. eCollection 2023. Front Pharmacol. 2023. PMID: 37033641 Free PMC article.
-
Development, testing, parameterisation, and calibration of a human PBPK model for the plasticiser, di-(2-ethylhexyl) terephthalate (DEHTP) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Feb 20;14:1140852. doi: 10.3389/fphar.2023.1140852. eCollection 2023. Front Pharmacol. 2023. PMID: 36891271 Free PMC article.
-
Advancing New Approach Methodologies (NAMs) for Tobacco Harm Reduction: Synopsis from the 2021 CORESTA SSPT-NAMs Symposium.Toxics. 2022 Dec 6;10(12):760. doi: 10.3390/toxics10120760. Toxics. 2022. PMID: 36548593 Free PMC article.
-
Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.Arch Toxicol. 2022 Dec;96(12):3407-3419. doi: 10.1007/s00204-022-03356-5. Epub 2022 Sep 5. Arch Toxicol. 2022. PMID: 36063173 Free PMC article.
-
Are Non-animal Systemic Safety Assessments Protective? A Toolbox and Workflow.Toxicol Sci. 2022 Aug 25;189(1):124-147. doi: 10.1093/toxsci/kfac068. Toxicol Sci. 2022. PMID: 35822611 Free PMC article.
References
-
- Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010 Mar;29(3):730–741. - PubMed
-
- Bessems J.G., Loizou G., Krishnan K., Clewell H.J., 3rd, Bernasconi C., Bois F., Coecke S., Collnot E.M., Diembeck W., Farcal L.R., Geraets L., Gundert-Remy U., Kramer N., Küsters G., Leite S.B., Pelkonen O.R., Schröder K., Testai E., Wilk-Zasadna I., Zaldívar-Comenges J.M. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA–EURL ECVAM ADME workshop. Regul. Toxicol. Pharmacol. 2014 Feb;68(1):119–139. Epub 2013 Nov 26. - PubMed
-
- Bessems J.G.M., Paini A., Gajewska M., Worth A. 2017. The Margin of Internal Exposure (MOIE) Concept for Dermal Risk Assessment Based on Oral Toxicity Data – a Case Study with Caffeine, Toxicology.http://doi.org/10.1016/j.tox.2017.03.012 Available online 10 March 2017, ISSN 0300-483X. - DOI - PMC - PubMed
-
- Bhat V.S., Meek M.E.B., Valcke M., English C., Boobis A., Brown R. Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance. Crit. Rev. Toxicol. 2017 - PubMed
-
- Binetti R., Costamagna F.M., Marcello I. Exponential growth of new chemicals and evolution of information relevant to risk control. Ann. Ist. Super. Sanita. 2008;44:13–15. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
